<DOC>
	<DOCNO>NCT02918279</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate effect liraglutide weight management pubertal adolescent subject obesity .</brief_summary>
	<brief_title>Effect Liraglutide Weight Management Pubertal Adolescent Subjects With Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age 12 less 18 year time signing informed consent le 18 year date randomisation BMI correspond equal 30 kg/m^2 adult international cutoff point equal 95th percentile age sex ( diagnosis obesity ) Stable body weight previous 90 day screen V2 ( 5 kg selfreported weight change ) History fail lose sufficient weight lifestyle modification judge investigator document subject 's medical record Prepubertal subject ( Tanner stage 1 ) screen V2 Type 1 diabetes mellitus ( T1DM ) Family personal history multiple endocrine neoplasia type 2 ( MEN2 ) Medullary thyroid carcinoma ( MTC ) History pancreatitis ( acute chronic ) Subjects secondary cause obesity ( i.e. , hypothalamic , genetic endocrine cause ) Treatment medication within 90 day screen V2 , base investigator 's judgement , may cause significant weight change . This also include treatment follow medication : pramlintide , orlistat , zonisamide , topiramate , lorcaserin , phenteremine , bupropion , naltrexone , glucagonlike peptide1 ( GLP1 ) receptor agonist , metformin ( use treatment obesity ) Antidiabetic treatment metformin History major depressive disorder within 2 year screen V2</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>